New England Journal of Medicine published the Phase 1 trial data on April 10, 2021 in original article entitled “Oncolytic HSV-1 Immunovirotherapy for Pediatric High-Grade Gliomas”
- G207 alone or in combination with radiation is well tolerated by pediatric patients
- G207 showed evidence of radiographic, neuropathological, or clinical response in 11 of 12 patients
- G207 converted immunologically “cold” tumors to “hot”
- Phase 2 program to launch in 2021 aimed at market approval for G207
Additionally, a presentation of the findings of the Phase I trial was made by Gregory K. Friedman, MD, University of Alabama Birmingham and the Phase 1 G207 clinical trial Principal Investigator, at the annual AACR (American Association for Cancer Research) virtual meeting on April 10, 2021.